Home
→
Browsing by Author

Browsing by Author "Rubio-Terrés, Carlos"

Now showing items 1-6 of 6

Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature

Grau Cerrato, Santiago; Miró, José María; Olalla, Julian; Alcalá, Juan C.; Castro, Antonio; Rubio-Rodríguez, Darío; Rubio-Terrés, Carlos (Taylor & Francis, 2023)

Introduction: Current recommended antiretroviral regimens include a combination of two (dual; DT) or three (triple; TT) antiretroviral drugs. This study aims to determine whether the quality of evidence from clinical trials ...
Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain

Grau Cerrato, Santiago; Azanza Perea, José Ramon; Ruiz, Isabel; Vallejo, Carlos; Mensa, Josep; Maertens, Johan; Heinz, Werner; Barrueta, Jon Andoni; Peral, Carmen; Mesa, Francisco Jesús; Barrado, Miguel; Charbonneau, Claudie; Rubio-Rodríguez, Darío; Rubio-Terrés, Carlos (Dove Medical Press, 2016)

OBJECTIVE: According to a recent randomized, double-blind clinical trial comparing the combination of voriconazole and anidulafungin (VOR+ANI) with VOR monotherapy for invasive aspergillosis (IA) in patients with hematologic ...
Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients.

Grau Cerrato, Santiago; Romá, E.; Salavert, M.; Barrueta, Jon Andoni; Peral, Carmen; Rodriguez, I.; Rubio-Rodríguez, Darío; Rubio-Terrés, Carlos (Auckland, NZ : Dove Medical Press, 2015)

OBJECTIVE: To estimate the cost-effectiveness of three echinocandins (anidulafungin, caspofungin, and micafungin) and generic fluconazole in the treatment of nonneutropenic adult patients with candidemia and/or invasive ...
Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

Isla, Dolores; De Castro, Javier; Juan, Oscar; Grau Cerrato, Santiago; Orofino, Javier; Gordo, Rocío; Rubio-Terrés, Carlos; Rubio-Rodríguez, Darío (Dove Medical Press, 2016)

OBJECTIVES: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an established treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutation. According to published meta-analyses, no ...
Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain

Rubio-Terrés, Carlos; Aguado, José María; Almirante, Benito; Cobo, Javier; Grau Cerrato, Santiago; Salavert, M.; González Antona Sánchez, Elena; López Gutiérrez, Cristina; Rubio-Rodríguez, Darío (SpringerOpen, 2019)

The cost of treating Clostridium difficile infection (CDI) in Spain is substantial. Findings from the randomised, controlled, open-label, phase 3b/4 EXTEND study showed that an extended-pulsed fidaxomicin (EPFX) regimen ...
¿Qué es una intervención sanitaria eficiente en España en 2020?

Sacristán, José Antonio; Oliva Moreno, Juan; Campillo Artero, Carlos; Puig i Junoy, Jaume; Pinto, José Luis; Dilla, Tatiana; Rubio-Terrés, Carlos; Ortún Rubio, Vicente (Elsevier, 2020)

Hace más de 15 años que en Gaceta Sanitaria se publicó el artículo titulado «¿Qué es una tecnología sanitaria eficiente en España?». El creciente interés por fijar el precio de las nuevas tecnologías en función del valor ...

Now showing items 1-6 of 6

Search DSpace

Advanced Search

Browse

All of DSpace

My Account

Compliant to Partaking

Browsing by Author "Rubio-Terrés, Carlos"

Browsing by Author "Rubio-Terrés, Carlos"

Search DSpace

Browse

All of DSpace

My Account